{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:20Z","timestamp":1740144140432,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:00:00Z","timestamp":1507593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s40264-017-0606-2","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T07:52:56Z","timestamp":1507621976000},"page":"267-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3669-6084","authenticated-orcid":false,"given":"Vicki","family":"Osborne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miranda","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad A. W.","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"issue":"4","key":"606_CR1","first-page":"239","volume":"10","author":"N Mobarra","year":"2016","unstructured":"Mobarra N, Shanaki M, Ehteram H, Nasiri H, Sahmani M, Saeidi M, et al. A review on iron chelators in treatment of iron overload syndromes. Int J Hematol Oncol Stem Cell Res. 2016;10(4):239\u201347.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"1","key":"606_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5662\/wjm.v6.i1.1","volume":"6","author":"CN Kontoghiorghe","year":"2016","unstructured":"Kontoghiorghe CN, Kontoghiorghes GJ. New developments and controversies in iron metabolism and iron chelation therapy. World J Methodol. 2016;6(1):1\u201319.","journal-title":"World J Methodol"},{"issue":"4","key":"606_CR3","first-page":"411","volume":"10","author":"E Poggiali","year":"2012","unstructured":"Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus Trasfus Sangue. 2012;10(4):411\u201322.","journal-title":"Blood Transfus Trasfus Sangue"},{"issue":"3","key":"606_CR4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.12833","volume":"98","author":"S Botzenhardt","year":"2017","unstructured":"Botzenhardt S, Li N, Chan EW, Sing CW, Wong ICK, Neubert A. Safety profiles of iron chelators in young patients with haemoglobinopathies. Eur J Haematol. 2017;98(3):198\u2013217.","journal-title":"Eur J Haematol"},{"unstructured":"Novartis. European Medicines Agency\u2014Exjade Summary of Product Characteristics [Internet]. 2017 [cited 2017 Apr 24]. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000670\/human_med_000780.jsp&mid=WC0b01ac058001d124 .","key":"606_CR5"},{"unstructured":"European Medicines Agency. European Medicines Agency\u2014Exjade European Public Assessment Report Scientific Discussion [Internet]. 2007 [cited 2017 Apr 24]. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000670\/human_med_000780.jsp&mid=WC0b01ac058001d124 .","key":"606_CR6"},{"doi-asserted-by":"crossref","unstructured":"Layton D, Shakir SA. Prescription-event monitoring. In: Strom BL, Kimmel SE, Sean Hennessy, editors. Pharmacoepidemiology. 5th ed. Chichester: Wiley; 2011. p. 301\u201330.","key":"606_CR7","DOI":"10.1002\/9781119959946.ch20"},{"unstructured":"Shimada M, Dass B, Ejaz AA. Assessment of elevated creatinine: BMJ Best Practice [Internet]. 2014 [cited 2017 Apr 24]. http:\/\/bestpractice.bmj.com\/best-practice\/monograph\/935.html .","key":"606_CR8"},{"issue":"7059","key":"606_CR9","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/bmj.313.7059.732","volume":"313","author":"BR McAvoy","year":"1996","unstructured":"McAvoy BR, Kaner EF. General practice postal surveys: a questionnaire too far? BMJ. 1996;313(7059):732\u20133 (discussion 733\u2013734).","journal-title":"BMJ"},{"issue":"9296","key":"606_CR10","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/S0140-6736(01)06898-2","volume":"358","author":"E Heeley","year":"2001","unstructured":"Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet Lond Engl. 2001;358(9296):1872\u20133.","journal-title":"Lancet Lond Engl"},{"issue":"7151","key":"606_CR11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bmj.317.7151.119","volume":"317","author":"RM Martin","year":"1998","unstructured":"Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed (\u201cblack triangle\u201d) drugs in general practice: observational study. BMJ. 1998;317(7151):119\u201320.","journal-title":"BMJ"},{"key":"606_CR12","volume-title":"Reporting adverse drug reactions. A guide for healthcare professionals","author":"British Medical Association","year":"2006","unstructured":"British Medical Association. Reporting adverse drug reactions. A guide for healthcare professionals. London: British Medical Association; 2006."},{"key":"606_CR13","volume-title":"International ethical guidelines for biomedical research involving human subjects","author":"Council for International Organizations of Medical Sciences","year":"2002","unstructured":"Council for International Organizations of Medical Sciences. International ethical guidelines for biomedical research involving human subjects. Geneva: Council for International Organizations of Medical Sciences; 2002."},{"unstructured":"Royal College of Physicians of London. Guidelines on the practice of Ethics Committees in Medical Research involving Human Subjects. London, UK; 1996.","key":"606_CR14"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0606-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0606-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0606-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T08:06:54Z","timestamp":1570176414000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0606-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0606-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2017,10,10]]}}}